Xin Lang Cai Jing·2026-03-27 06:53Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a positive market sentiment towards the company [1][4]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business segments include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - Revenue composition is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - Southern Fund has a significant holding in Tiger Med through the Southern CSI Innovative Drug Industry ETF (159858), which held 163,000 shares in the fourth quarter, representing 2.86% of the fund's net value, making it the ninth largest holding [2][5]. - The ETF has generated a floating profit of approximately 413,900 CNY today and 528,000 CNY during the three-day increase [2][5]. - The Southern CSI Innovative Drug Industry ETF was established on March 12, 2021, with a current size of 324 million CNY. Year-to-date, it has experienced a loss of 7.1%, ranking 4816 out of 5563 in its category, while it has gained 8.26% over the past year, ranking 3387 out of 4429 [2][5].